Tourmaline Bio, Inc. (TRML) Stock Price & Growth Analysis

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

Tourmaline Bio, Inc.

TRML

NASDAQ

Unprofitable

407M

Biotechnology

Next Earning date - 14 Aug 2025

407M

Biotechnology

Next Earning date - 14 Aug 2025

15.83USD

-0.16 ( -1.00%)

Pre-market 16.04$

0.21 (1.33%)

Market Closed (as of Jul 01, 20:00 EDT)

Relative Strenght

Volume Buzz

-41%

Earning Acce

Dist 52w H.

47%

Overview Chart

Quote Panel

Updated July 2, 2025

1W -5.27 % 1M -14.15 % 3M 20.66 % 1Y 23.38 %

Key Metrics

Market Cap
406.65M
Shares Outstanding
25.69M
Share in Float
16.37M
Dividende
0

Earning Date
14 Aug 2025
Price Target
15.83
Average Volume
327631
Beta
2.0621152

Range
11.56-29.788
Industry
Biotechnology
Website
https://www.tourmalinebio.com
Sector
Healthcare

Quote Panel

Updated July 2, 2025

1W % 1M % 3M % 1Y %

Key Metrics

Market Cap
Shares Outstanding
Share in Float
Dividende

Earning Date
No Data
Price Target
Average Volume
Beta

Range
Industry
Website
Sector

Fundamentals

N/A

P/E Ratio

10166.22x

P/S Ratio

1.45x

P/B Ratio

0.0

Debt/Equity

-207172.5%

Net Margin

$-3.2

EPS

How TRML compares to sector?

P/E Ratio

Fundamentals

Relative Strength

TRML

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Relative Strength

TRML

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

$7M

NaN%

2026-Revenue

$4.15

-367%

2026-EPS

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Buy

Price Target

0.00(-100.00%)

Number of analyst

Last analyst upgrade/downgrade

Wedbush

initialise

Previous: Not converted

2025-03-06

Now: Outperform

BMO Capital

initialise

Previous: Not converted

2024-12-05

Now: Outperform

Cantor Fitzgerald

initialise

Previous: Not converted

2024-10-15

Now: Overweight

Earnings Growth

YoY

Current

Estimates

Q2.23

N/A

-0.20
vs -0.00

Q3.23

N/A

-1.64
vs -0.00

Q4.23

N/A

-0.81
vs -0.00

Q1.24

N/A

-0.55
vs -0.37

Q2.24

N/A

-0.68
vs -0.20

Q3.24

N/A

-0.78
vs -1.64

Q4.24

N/A

-0.86
vs -0.81

Q1.25

N/A

-0.89
vs -0.55

Q2.25

N/A

-0.93
vs -0.68

Q3.25

N/A

-0.94
vs -0.78

Sales Growth

YoY

Current

Estimates

Q4.22

NA vs NA

Q1.23

NA vs NA

Q2.23

NA vs NA

Q3.23

NA vs NA

Q4.23

2.3M vs NA

Q1.24

NA vs NA

Q2.24

NA vs NA

Q3.24

NA vs NA

Q4.24

-98%

40K vs 2.3M

Q1.25

NA vs NA

Return on Equity

QoQ

Q2.23

+38%

0.38
vs -0.05

Q3.23

-5%

-0.05
vs 0.38

Q4.23

+1%

0.01
vs -0.05

Q1.24

-4%

-0.04
vs 0.01

Q2.24

-5%

-0.05
vs -0.04

Q3.24

-6%

-0.06
vs -0.05

Q4.24

-7%

-0.07
vs -0.06

Q1.25

-8%

-0.08
vs -0.07

Institutionnal Ownership

QoQ

Q4.23

54
vs NA

Q1.24

105

105
vs 54

94%

Q2.24

86
vs 105

-18%

Q3.24

92
vs 86

Q4.24

100

100
vs 92

Q1.25

112

112
vs 100

12%

Earnings Growth

Latest News

globenewswire.com

7 hours ago

Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

globenewswire.com

7 hours ago

Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

globenewswire.com

7 hours ago

Tourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025

globenewswire.com

7 hours ago

Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker

seekingalpha.com

16 hours ago

Tourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 Inhibition

globenewswire.com

16 hours ago

Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025

Company Description

15.83USD

N/A

10166.22x

1.45x

0.0

-207172.5%

$-3.2

$7M

$4.15

Earnings Growth

Latest News

Company Description

15.83USD

N/A

10166.22x

1.45x

0.0

-207172.5%

$-3.2